Inari Medical Q2 EPS Estimate Lowered by Leerink Partnrs

Inari Medical, Inc. (NASDAQ:NARI) – Equities researchers at Leerink Partnrs reduced their Q2 2025 earnings estimates for Inari Medical in a research report issued on Tuesday, October 15th. Leerink Partnrs analyst M. Kratky now expects that the company will post earnings per share of ($0.01) for the quarter, down from their prior estimate of $0.03. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Inari Medical’s current full-year earnings is ($0.70) per share. Leerink Partnrs also issued estimates for Inari Medical’s Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at $0.02 EPS, FY2027 earnings at $0.57 EPS and FY2028 earnings at $1.01 EPS.

Several other equities research analysts have also recently commented on the company. Piper Sandler reaffirmed a “neutral” rating and set a $50.00 price objective on shares of Inari Medical in a research report on Monday, August 26th. Robert W. Baird decreased their price target on shares of Inari Medical from $65.00 to $63.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 31st. William Blair initiated coverage on shares of Inari Medical in a research report on Thursday, July 25th. They set an “outperform” rating for the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Inari Medical in a report on Wednesday, October 9th. Finally, Canaccord Genuity Group boosted their price target on Inari Medical from $55.00 to $71.00 and gave the company a “buy” rating in a report on Wednesday, July 31st. Six research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $57.44.

Inari Medical Stock Performance

NASDAQ:NARI opened at $43.47 on Thursday. The firm has a 50-day simple moving average of $44.30 and a two-hundred day simple moving average of $45.87. Inari Medical has a fifty-two week low of $36.73 and a fifty-two week high of $67.13. The firm has a market cap of $2.53 billion, a P/E ratio of -106.02 and a beta of 1.00.

Inari Medical (NASDAQ:NARI) last issued its quarterly earnings results on Tuesday, July 30th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.25). The company had revenue of $145.82 million for the quarter, compared to the consensus estimate of $143.96 million. Inari Medical had a negative net margin of 10.42% and a negative return on equity of 7.51%.

Insider Activity at Inari Medical

In other news, CEO Andrew Hykes sold 3,000 shares of the business’s stock in a transaction on Monday, July 22nd. The shares were sold at an average price of $55.23, for a total value of $165,690.00. Following the transaction, the chief executive officer now owns 455,252 shares of the company’s stock, valued at approximately $25,143,567.96. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CFO Mitch C. Hill sold 5,000 shares of the stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $47.99, for a total transaction of $239,950.00. Following the completion of the transaction, the chief financial officer now directly owns 179,600 shares of the company’s stock, valued at approximately $8,619,004. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Andrew Hykes sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, July 22nd. The shares were sold at an average price of $55.23, for a total value of $165,690.00. Following the transaction, the chief executive officer now owns 455,252 shares of the company’s stock, valued at $25,143,567.96. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 51,000 shares of company stock valued at $2,374,230. 10.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Inari Medical

Hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. lifted its stake in shares of Inari Medical by 6.9% in the 4th quarter. Vanguard Group Inc. now owns 5,038,292 shares of the company’s stock valued at $327,086,000 after purchasing an additional 325,586 shares during the last quarter. State of Alaska Department of Revenue raised its stake in shares of Inari Medical by 462.4% in the first quarter. State of Alaska Department of Revenue now owns 31,095 shares of the company’s stock valued at $1,491,000 after acquiring an additional 25,566 shares during the period. Maryland State Retirement & Pension System purchased a new stake in shares of Inari Medical in the first quarter valued at $886,000. BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of Inari Medical in the 1st quarter worth about $30,000. Finally, Texas Permanent School Fund Corp boosted its stake in shares of Inari Medical by 1.5% during the 1st quarter. Texas Permanent School Fund Corp now owns 44,858 shares of the company’s stock worth $2,152,000 after purchasing an additional 664 shares during the period. Hedge funds and other institutional investors own 90.98% of the company’s stock.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.